Business Context and Reporting Period
This Form 8-K is a current report filed by Spherix Incorporated (not Dominari Holdings Inc.) on June 19, 2019. The filing addresses Item 8.01 (Other Events) regarding the proposed acquisition of assets from CBM BioPharma, Inc. ("CBM"). The Company previously entered into an Asset Purchase Agreement on May 15, 2019, and amended it on May 30, 2019. On the filing date, Spherix announced the filing of a preliminary proxy statement to seek stockholder approval for the transaction.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. This document serves as a notification of a corporate event rather than a financial performance report.
Material Changes and Transaction Details
- Asset Acquisition: Spherix agreed to purchase certain assets from CBM, including a license agreement for technologies targeting acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acral lentiginous melanoma, and pancreatic cancer.
- Additional Assets: The acquisition includes university contracts and contracts with a chief scientist and an advisory board.
- Amendment: On May 30, 2019, the agreement was amended to include a termination fee upon the occurrence of certain events.
- Current Status: A preliminary proxy statement was filed on June 18, 2019, and a press release was issued on June 19, 2019, to solicit stockholder approval.
Guidance, Outlook, and Risks
Management provided forward-looking statements regarding the anticipated benefits of the transaction and the future of the combined company. However, the filing explicitly disclaims any obligation to update these statements and notes that actual results may differ materially due to various risks.
- Key Risks: Failure to obtain regulatory approvals or stockholder approval; delays in consummating the transaction; difficulties in integrating CBM's assets; changes in the business environment (inflation, interest rates); and competitive product activity.
- Outlook: The Company anticipates future opportunities for the combined entity but emphasizes that the transaction is subject to contingencies.
Investor Verification Checklist
- Verify the terms of the Asset Purchase Agreement and the specific termination fee details in the preliminary proxy statement.
- Confirm the status of required regulatory approvals and the timeline for the stockholder vote.
- Review the definitive proxy statement for detailed financial implications and valuation of the CBM assets.
- Assess the specific risks related to the integration of the acquired technologies in AML, ALL, melanoma, and pancreatic cancer.
- Check for any subsequent filings regarding the outcome of the stockholder vote or changes to the transaction terms.